Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. (CTMX) Stock Overview

Explore CytomX Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

CTMX●NASDAQ
HealthcareBiotechnology
$3.25
$0.010(0.31%)
U.S. Market opens in 15h 20m

CytomX Therapeutics, Inc. (CTMX)

Meyka AI Score

Z

Key Financials

Market Cap522.7M
P/E Ratio-9.21
EPS (TTM)$-0.41
ROE-0.37%
Fundamental Analysis

AI Price Forecasts

1 Month$3.34
3 Months$2.17
1 Year Target$5.84

CTMX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of CytomX Therapeutics, Inc. (NASDAQ: CTMX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, CytomX Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CTMX on the NASDAQ shows an RSI of 39.28, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $5.84 for the NASDAQ listing.

Key metrics behind CytomX Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -9.21 and a market capitalization of 522.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CTMX on the NASDAQ.

Price Performance (NASDAQ: CTMX)

1-Day Change
0.31%
5-Day Change
-4.41%
1-Month Change
-4.41%
3-Month Change
-24.24%
6-Month Change
-45.19%
Year-to-Date (YTD) Change
-23.71%
1-Year Change
35.98%
3-Year Change
90.06%
5-Year Change
-40.26%
All-Time (Max) Change
-74.81%

Contact Information

https://www.cytomx.com
650 515 3185
151 Oyster Point Boulevard, South San Francisco, CA, 94080

Company Facts

690 Employees
IPO DateOct 8, 2015
CountryUS
Actively Trading

Frequently Asked Questions